Banner Image

Test Directory

c-kit Mutation Analysis, Cell-based

Order Code: CKITMT

Test Summary

Activating c-KIT mutations have been identified in various human cancers. c-KIT exon 8 and 17 mutations have been described in patients with CBF-AMLs and usually confer a poor prognosis with increased relapse rate. c-KIT exon 9, 11, 13, 17 mutations have been reported in nearly 90% GIST patients. The presence mutation usually predict poor survival. c-KIT exon 17 mutation has been reported in patients with systemic mastocytosis.

Aliases

  • N/A

Specimen Collection

Order Code

CKITMT

EPIC (Premier) Code

LAB5221

Includes

N/A

CPT Code

  • 81272

Billing Code

  • 670208

CPT Statement

Methodology

Next Generation Sequencing

FDA Status

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Physician Attestation of Informed Consent

N/A

Testing Laboratory

Quest Diagnostics Nichols Institute
33608 Ortega Highway
San Juan Capistrano CA, 92675

Department

Reference Testing

Reference Range

Not detected

Setup Schedule / Expected Turnaround Time

Monday, Thursday; Report available: 3 days

Specimen Collection

Billing

CPT Code

  • 81272

Billing Code

  • 670208

CPT Statement

Result Information

Methodology

Next Generation Sequencing

Testing Laboratory

N/A

Reference Range

Not detected

Setup Schedule / Expected Turnaround Time

Monday, Thursday; Report available: 3 days